BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $27.35 billion. The enterprise value is $10.59 billion.
Important Dates
The last earnings date was Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 250.93 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 250.93M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -1.02% |
| Owned by Insiders (%) | 17.57% |
| Owned by Institutions (%) | 21.64% |
| Float | 104.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.07 |
| Forward PS | 13.02 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.12 |
| Quick Ratio | 6.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -54.07 |
Financial Efficiency
Return on equity (ROE) is -3.04% and return on invested capital (ROIC) is -2.64%.
| Return on Equity (ROE) | -3.04% |
| Return on Assets (ROA) | -2.30% |
| Return on Invested Capital (ROIC) | -2.64% |
| Return on Capital Employed (ROCE) | -4.21% |
| Revenue Per Employee | $546,192 |
| Profits Per Employee | -$99,034 |
| Employee Count | 6,772 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 2.09 |
Taxes
In the past 12 months, BioNTech SE has paid $57.96 million in taxes.
| Income Tax | 57.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.11% in the last 52 weeks. The beta is 1.41, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -4.11% |
| 50-Day Moving Average | 99.06 |
| 200-Day Moving Average | 102.93 |
| Relative Strength Index (RSI) | 70.65 |
| Average Volume (20 Days) | 1,138,190 |
Short Selling Information
| Short Interest | 4.97M |
| Short Previous Month | 5.66M |
| Short % of Shares Out | 4.83% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.45 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.70 billion and -$670.66 million in losses. Loss per share was -$2.80.
| Revenue | 3.70B |
| Gross Profit | 3.05B |
| Operating Income | -945.21M |
| Pretax Income | -612.70M |
| Net Income | -670.66M |
| EBITDA | -548.87M |
| EBIT | -945.21M |
| Loss Per Share | -$2.80 |
Full Income StatementBalance Sheet
The company has $17.05 billion in cash and $287.93 million in debt, with a net cash position of $16.76 billion or $66.78 per share.
| Cash & Cash Equivalents | 17.05B |
| Total Debt | 287.93M |
| Net Cash | 16.76B |
| Net Cash Per Share | $66.78 |
| Equity (Book Value) | 21.68B |
| Book Value Per Share | 90.16 |
| Working Capital | 15.97B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$371.70 million and capital expenditures -$209.43 million, giving a free cash flow of -$574.66 million.
| Operating Cash Flow | -371.70M |
| Capital Expenditures | -209.43M |
| Free Cash Flow | -574.66M |
| FCF Per Share | -$2.29 |
Full Cash Flow StatementMargins
Gross margin is 82.49%, with operating and profit margins of -25.55% and -18.13%.
| Gross Margin | 82.49% |
| Operating Margin | -25.55% |
| Pretax Margin | -16.56% |
| Profit Margin | -18.13% |
| EBITDA Margin | -14.84% |
| EBIT Margin | -25.55% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.40% |
| Shareholder Yield | 0.40% |
| Earnings Yield | -2.45% |
| FCF Yield | -2.10% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $140.31, which is 28.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $140.31 |
| Price Target Difference | 28.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 3.50% |
| EPS Growth Forecast (5Y) | -13.37% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.95 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.95 |
| Piotroski F-Score | 2 |
